Label (71610 0947 30)
Pregabalin Capsule
Product Images NDC 71610-947
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71610-947). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Aphena (Aphena)
Chemical Structure (Pregabalin 01)
Figure 1 (Pregabalin 02)
Figure 2 (Pregabalin 03)
Figure 3 (Pregabalin 04)
This evaluation compares the percentage of patients showing improvement in pain levels with different doses of Pregabalin (300mg, 150mg, and 75mg two times a day) and a placebo. The percentages of improvement in pain levels are displayed visually in a graph.*
Figure 4 (Pregabalin 05)
This is a report showing the percentage of patients whose pain improved with different treatments. Pregabalin at 200 mg three times a day led to a significant improvement, followed by pregabalin at 100 mg three times a day, and finally placebo. The chart includes data points indicating the percent improvement in pain from baseline for each treatment group.*
Figure 5 (Pregabalin 06)
This text provides information on the percent of patients improved with different treatments: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and Placebo, measured in terms of percent improvement in pain from baseline. It presents data points ranging from 20 to 100 percent improvement.*
Figure 6 (Pregabalin 07)
Figure 7 (Pregabalin 08)
Seizure Reduction data for three different studies (E1, E2, E3) at varying dosages of Pacabo. The table shows the median percentage change from baseline in seizure frequency. The studies were conducted at different dosing frequencies (BID - twice a day, TID - three times a day).*
Figure 9 (Pregabalin 09)
This text provides information on the percentage of patients improved with different doses of Pregabalin and a Placebo. The doses mentioned are 600 mg, 450 mg, and 300 mg per day. The data includes measurements taken at different intervals to indicate the improvement in pain from the baseline.*
Figure 10 (Pregabalin 10)
Figure 11 (Pregabalin 11)
This text provides information on the percentage of subjects that improved from baseline to Week 12 in a particular study. The data seems to be represented in a numerical format, showing different values for improvement percentages at different time points. The text seems to be focuses on analyzing the improvement of subjects over a certain period of time.*
Figure 12 (Pregabalin 12)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
